- D64.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2024 edition of ICD-10-CM D64.81 became effective on October 1, 2022.
- This is the American ICD-10-CM version of D64.81 – other international versions of ICD-10 D64.81 may differ.
ICD-10-CM D64.81 is grouped within Diagnostic Related Group(s):
Applicable To
- Antineoplastic chemotherapy induced anemia
Type 2 Excludes
- anemia in neoplastic disease (D63.0)
- aplastic anemia due to antineoplastic chemotherapy (D61.1)
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2016 (effective 10/1/2015): No change
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2024 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to D64.81:
- due to (in) (with) > Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) D64.9
- antineoplastic chemotherapy > due to (in) (with) D64.81
- chemotherapy, antineoplastic > due to (in) (with) D64.81